Witryna5 paź 2024 · IMGN632, a CD123-targeting antibody-drug conjugate (ADC), is in clinical development for the treatment of hematologic malignancies like BPDCN, acute myeloid leukemia (AML), and acute lymphocytic leukemia in clinical trials. The agent is under evaluation as monotherapy in patients with BPDCN and minimal residual disease … WitrynaMenu. Stanford Medicine Explore Stanford Medicine. Health Care . Find a doctor; Adult-care doctor; Pediatrician or pediatric specialist
FDA Grants Breakthrough Therapy Designation to CD123 …
WitrynaBrief Summary: This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when … Witryna20 maj 2024 · In addition, IMGN632 monotherapy is being explored in expansion cohorts of MRD-positive patients to assess conversion rate from MRD+ to MRD-, in fit and unfit AML subpopulations. Clinical trial ... five letter words with nea
IMGN632 on Blastic Plasmacytoid Dendritic Cell Neoplasm and
Witryna9 gru 2024 · Together with the preclinical data on combining IMGN632 with azacitidine and venetoclax presented by our collaborators from MD Anderson, these updated clinical results provide a strong foundation for our ongoing expansion of IMGN632 monotherapy studies in BPDCN, AML, and ALL, and the recent initiation of our trial to evaluate … Witryna摘要 在过去的十年里,急性髓系白血病(AML)的靶向治疗药物研发呈现出井喷式的势头,为AML患者的精准治疗奠定了坚实的基础。. 本文综述了近期在AML治疗领域进展较快的4类靶向药物(靶向基因或信号通路改变、靶向细胞凋亡相关通路、靶向细胞表面抗原以及 ... Witryna11 kwi 2024 · Patients enrolled onto the monotherapy Phase 1 arm will be grouped by disease type (acute myeloid leukemia [AML], B-cell acute lymphoblastic leukemia … can i sell my swgoh account